MAIA Biotechnology, Inc.
MAIAMAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Q3 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How MAIA's past catalysts played out
6-Thio-2'-Deoxyguanosine
Carcinoma, Non-Small-Cell Lung
Vinorelbine
Carcinoma, Non-Small -Cell Lung
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
6-Thio-2'-Deoxyguanosine | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Vinorelbine | Phase 3 | Carcinoma, Non-Small -Cell Lung | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MAIA Biotechnology, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in MAIA Biotechnology, Inc.'s (MAIA) pipeline across Phase 3. Its lead program is 6-Thio-2'-Deoxyguanosine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MAIA Biotechnology, Inc.'s next FDA catalyst?→
MAIA Biotechnology, Inc.'s (MAIA) next tracked catalyst is a Phase 3 expected July 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MAIA biotech catalysts?→
Add MAIA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MAIA Biotechnology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.